Square Pharmaceuticals (SQURPHARMA) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
10 Nov, 2026Executive summary
Q1 FY26/27 consolidated net revenue was Tk 22.44bn vs Tk 21.59bn YoY; profit for the period was Tk 7.78bn vs Tk 7.40bn.
Consolidated EPS increased to Tk 8.77 from Tk 8.35; cash and cash equivalents stood at Tk 55.41bn at 30 Sep 2026.
Financial highlights
Consolidated gross profit was Tk 12.18bn vs Tk 11.24bn; profit from operations was Tk 7.60bn vs Tk 7.02bn.
Consolidated profit before tax reached Tk 8.85bn vs Tk 8.35bn; income tax expense was Tk 1.68bn vs Tk 1.54bn.
Standalone net revenue was Tk 17.59bn vs Tk 16.39bn; profit after tax was Tk 4.95bn vs Tk 4.70bn.
Key financial ratios and metrics
Consolidated NAV per share was Tk 187.35 at 30 Sep 2026, up from Tk 178.99 at 30 Jun 2026.
Consolidated net operating cash flow per share fell to Tk 5.49 from Tk 7.55 YoY; standalone NOCF per share was Tk 5.05 vs Tk 7.15.
Latest events from Square Pharmaceuticals
- Strong revenue and profit growth, with higher EPS and robust operating cash flow.SQURPHARMA
Q3 2026 - Six-month net profit surged 16% year-over-year on strong revenue and cash flow growth.SQURPHARMAQ2 25/26
- Consolidated profit up 14.54% with strong exports and a 120% cash dividend; standalone profit dipped.SQURPHARMAQ4 24/25
- Net revenue grew 21.7% and net profit after tax rose 21.5% year-over-year in Q1 FY2025-26.SQURPHARMAQ1 25/26
- Consolidated profit up 10.26% on strong exports and subsidiary growth; dividend raised.SQURPHARMAQ4 23/24
- Consolidated Q1 profit was stable, with EPS up and cash flow per share down year-over-year.SQURPHARMAQ1 24/25
- Double-digit profit and revenue growth, strong balance sheet, and robust investment income.SQURPHARMAQ3 2025
- Net profit up 13% to Tk. 12.70B; EPS and NAV per share both increased year-over-year.SQURPHARMAQ2 2025
- Net profit rose 13% year-over-year, with EPS at Tk. 14.32 and strong asset growth.SQURPHARMAQ2 24/25